Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Beta-Amyloid (1-11) Research Applications, Clinical Value, a

    2025-07-19

    Beta-Amyloid (1-11): Research Applications, Clinical Value, and Future Directions in Neurodegenerative Disease Studies
    Introduction [Related: clozapine-n-oxide]
    Beta-Amyloid (1-11) is a synthetic peptide fragment corresponding to the N-terminal region of the full-length amyloid-beta (Aβ) peptide, which is a central biomolecule implicated in the pathogenesis of Alzheimer’s disease (AD) and other neurodegenerative disorders. The Aβ peptide is derived from the amyloid precursor protein (APP) via sequential cleavage by β- and γ-secretases, resulting in peptides of varying lengths, most notably Aβ1-40 and Aβ1-42. The Beta-Amyloid (1-11) fragment, comprising the first eleven amino acids of the Aβ sequence (DAEFRHDSGYE), has emerged as a valuable research tool for investigating the early aggregation events, immunogenic epitopes, and molecular interactions associated with amyloid pathology (Masters et al., 1985, EMBO J). [Related: p-pi3k] Mechanistically, Beta-Amyloid (1-11) is not itself neurotoxic or prone to aggregation like the longer Aβ peptides, but it represents a critical region involved in antibody recognition and is a target for diagnostic and therapeutic antibody development (Saido et al., 1996, J Biol Chem). Its use in research extends to epitope mapping, immunoassay development, and as a control peptide in studies of Aβ aggregation and toxicity. The availability of high-purity synthetic Beta-Amyloid (1-11) enables reproducible experimental designs and supports the advancement of both basic and translational neuroscience research.
    [Related: cno chemical name] Clinical Value and Applications
    The clinical value of Beta-Amyloid (1-11) lies primarily in its utility as a research reagent rather than a direct therapeutic agent. Its applications are multifaceted:
    1. **Epitope Mapping and Antibody Development:** The N-terminal region of Aβ, represented by Beta-Amyloid (1-11), is a major immunogenic epitope. Monoclonal antibodies targeting this region, such as 6E10, are widely used in immunohistochemistry and ELISA assays for the detection and quantification of Aβ in biological samples (Kim et al., 2012, J Neurochem).
    2. **Assay Development:** Beta-Amyloid (1-11) serves as a standard or control peptide in the development of immunoassays, facilitating the detection of Aβ species in cerebrospinal fluid (CSF), plasma, and brain tissue. This is critical for biomarker discovery and validation in AD research (Blennow et al., 2010, Nat Rev Neurol).
    3. **Aggregation Studies:** While Beta-Amyloid (1-11) itself does not aggregate, it is used as a negative control in aggregation assays, helping to delineate the sequence requirements for Aβ oligomerization and fibril formation (Harmeier et al., 2009, J Biol Chem).
    4. **Vaccine and Immunotherapy Research:** The N-terminal Aβ epitope is a focus for active and passive immunization strategies. Beta-Amyloid (1-11) is used to evaluate immune responses and antibody specificity in preclinical vaccine studies (Lemere et al., 2003, J Neurosci).
    5. **Structural and Biophysical Studies:** The peptide is employed in NMR and crystallography experiments to elucidate the conformational properties of Aβ and its interactions with small molecules or antibodies (Barrow et al., 1992, J Mol Biol).
    Key Challenges and Pain Points Addressed
    Research into Alzheimer’s disease and related neurodegenerative disorders faces several key challenges, many of which are addressed by the use of Beta-Amyloid (1-11):
    - **Specificity in Detection:** Full-length Aβ peptides are heterogeneous and prone to aggregation, complicating their use in immunoassays. Beta-Amyloid (1-11) provides a defined, stable epitope for antibody binding, improving assay specificity and reproducibility (Kim et al., 2012).
    - **Standardization of Research Tools:** Variability in peptide preparations can lead to inconsistent results across laboratories. Synthetic Beta-Amyloid (1-11) of high purity ensures standardized conditions for comparative studies (APExBIO, 2024).
    - **Understanding Early Pathogenic Events:** The initial molecular events leading to Aβ aggregation and toxicity are not fully understood. By isolating the N-terminal region, researchers can dissect its role in aggregation kinetics and immune recognition (Harmeier et al., 2009).
    - **Development of Immunotherapies:** Immunotherapies targeting Aβ require precise knowledge of immunogenic epitopes. Beta-Amyloid (1-11) enables the characterization of antibody specificity and cross-reactivity, informing the design of safer and more effective therapeutics (Lemere et al., 2003).
    Literature Review
    A review of the scientific literature highlights the significance of Beta-Amyloid (1-11) in neurodegenerative disease research:
    1. **Masters et al. (1985, EMBO J):** This seminal study first characterized the Aβ peptide and identified the N-terminal region as a critical domain for antibody recognition and plaque formation in AD brains.
    2. **Saido et al. (1996, J Biol Chem):** The authors demonstrated that the N-terminal region of Aβ is essential for the generation of neoepitopes recognized by diagnostic antibodies, underscoring the importance of Beta-Amyloid (1-11) in immunoassay development.
    3. **Barrow et al. (1992, J Mol Biol):** This study used synthetic Aβ fragments to investigate the structural determinants of aggregation, revealing that the N-terminal residues modulate the conformational dynamics of the peptide.
    4. **Lemere et al. (2003, J Neurosci):** The researchers evaluated the immunogenicity of N-terminal Aβ peptides in vaccine models, showing that Beta-Amyloid (1-11) elicits robust antibody responses without inducing T-cell-mediated toxicity.
    5. **Kim et al. (2012, J Neurochem):** This paper described the use of N-terminal Aβ peptides in the development of sensitive and specific ELISA assays for CSF biomarker analysis in AD patients.
    6. **Blennow et al. (2010, Nat Rev Neurol):** The review emphasized the need for standardized biomarker assays in AD research, highlighting the role of defined peptides such as Beta-Amyloid (1-11) in assay calibration and validation.
    7. **Harmeier et al. (2009, J Biol Chem):** The authors explored the aggregation properties of truncated Aβ peptides, demonstrating that the N-terminal region influences the kinetics and morphology of amyloid fibrils.
    Experimental Data and Results
    Experimental studies utilizing Beta-Amyloid (1-11) have yielded several important findings:
    - **Antibody Binding:** ELISA and surface plasmon resonance (SPR) assays have shown that monoclonal antibodies such as 6E10 bind specifically to Beta-Amyloid (1-11), confirming its utility as an epitope standard (Kim et al., 2012).
    - **Aggregation Assays:** Thioflavin T fluorescence and electron microscopy studies indicate that Beta-Amyloid (1-11) does not form amyloid fibrils under physiological conditions, validating its use as a negative control in aggregation experiments (Harmeier et al., 2009).
    - **Immunogenicity:** Preclinical vaccine studies in transgenic mouse models have demonstrated that immunization with Beta-Amyloid (1-11) conjugated to carrier proteins induces high-titer, Aβ-specific antibodies without eliciting T-cell-mediated adverse effects (Lemere et al., 2003).
    - **Assay Calibration:** The use of Beta-Amyloid (1-11) as a standard in immunoassays has improved the sensitivity and specificity of Aβ detection in CSF and plasma samples from AD patients, facilitating early diagnosis and monitoring (Blennow et al., 2010).
    - **Structural Studies:** NMR spectroscopy of Beta-Amyloid (1-11) has provided insights into the conformational flexibility of the N-terminal region, informing the design of peptide-based inhibitors and diagnostic probes (Barrow et al., 1992).
    Usage Guidelines and Best Practices
    To maximize the utility of Beta-Amyloid (1-11) in research applications, the following guidelines are recommended:
    1. **Peptide Handling:** Beta-Amyloid (1-11) should be reconstituted in sterile, deionized water or appropriate buffer at the recommended concentration. Aliquots should be stored at -20°C or lower to prevent degradation.
    2. **Assay Development:** When using Beta-Amyloid (1-11) as a standard or control, ensure that peptide purity is ≥95% and confirm sequence identity by mass spectrometry. Include appropriate negative and positive controls in all assays.
    3. **Immunization Protocols:** For vaccine studies, conjugate Beta-Amyloid (1-11) to a carrier protein (e.g., KLH) to enhance immunogenicity. Use Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 21 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11580655